Mark Bodenrader - 01 Jun 2022 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc.

Role: Title: Interim Chief Financial Officer, Vice President, Finance and Chief Accounting Officer
Signature: /s/ Mark Bodenrader
Issuer symbol: N/A
Transactions as of: 01 Jun 2022
Net transactions value: $0
Form type: 4
Filing time: 03 Jun 2022, 16:45:19 UTC
Previous filing: 11 Feb 2022
Next filing: 08 Feb 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CERE	Restricted Stock Units	Award	$0	+18,932		$0.000000	18,932	01 Jun 2022	Common Stock	18,932		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock.
F2	25% of the RSUs shall vest on each of the first, second, third and fourth anniversary of June 1, 2022, subject to the Reporting Person's continued service relationship with the Issuer through each such date.

Remarks:

Title: Interim Chief Financial Officer, Vice President, Finance and Chief Accounting Officer